Nature Methods:科学家研发人工胸腺,有望逆转癌症治疗

2017-04-05 佚名 来宝网

加州大学洛杉矶分校(UCLA)的研究小组创建了一个全新的系统来产生人类T细胞,这种白细胞可以对抗外来病毒的侵略,系统工程师可以利用这一系统来发现并攻击癌细胞,这就意味着我们向战胜癌症又前进了一步。

加州大学洛杉矶分校(UCLA)的研究小组创建了一个全新的系统来产生人类T细胞,这种白细胞可以对抗外来病毒的侵略,可以利用这一系统来发现并攻击癌细胞,这就意味着我们向战胜癌症又前进了一步。

完整的研究报告发表于《NATURE METHODS》杂志中。

胸腺位于心脏前,在整个免疫系统中发挥着至关重要的作用,它使用血液干细胞生成T细胞,帮助身体抵抗感染,有能力消除癌细胞。然而,随着人们年龄的增长或生病,胸腺没有有效地使T细胞。胸腺中生成T细胞是需要专门的分子的,也称之为受体,这些受体帮助T细胞找到病毒来源或者癌细胞。利用好这一过程有可能成为治疗癌症的有效途径,科学家发现,用这些特定的癌细胞发现受体层层包围T细胞在临床阶段取得了可喜的效果,这一过程被称为T细胞过继免疫治疗。

T细胞过继免疫治疗的过程包括,首先从癌症患者体内取得T细胞,在实验室中,将这些T细胞把癌症发现受体结合,继而再注入回病人体内。

然而,T细胞过继免疫治疗可能需要耗费一定的时间,而且癌症患者体内是否有充足的T细胞也是一个问题。因此,研究小组用这些成分创建了人工胸腺,结构宛如人的胸腺,可以从血液中生成T细胞,科学家发现人工胸腺中可以生成大量的T细胞,它们与癌症发现受体相结合,作用工程与人体的胸腺非常相似。

相信这一研究可以为癌症治疗带来逆转性的新方法。

原始出处:

Christopher S Seet, Chongbin He, et al.  Generation of mature T cells from human hematopoietic stem and progenitor cells in artificial thymic organoids.  Nature Methods (2017) doi:10.1038/nmeth.4237

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1663472, encodeId=ed1c16634e2b1, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Fri Mar 02 23:10:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844207, encodeId=bc1a184420e8c, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Fri May 26 01:10:00 CST 2017, time=2017-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800954, encodeId=27781800954c1, content=<a href='/topic/show?id=3075e3328f7' target=_blank style='color:#2F92EE;'>#研发人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73328, encryptionId=3075e3328f7, topicName=研发人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Jan 24 08:10:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896015, encodeId=35ce18960159a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Sep 01 12:10:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881853, encodeId=38dd18818534a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 08 11:10:00 CST 2017, time=2017-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300000, encodeId=2eda130000035, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Apr 07 05:10:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185348, encodeId=15381853486e, content=反复实践,反复学习,认真推敲,不断提高自己的业务水平。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Wed Apr 05 15:43:36 CST 2017, time=2017-04-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1663472, encodeId=ed1c16634e2b1, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Fri Mar 02 23:10:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844207, encodeId=bc1a184420e8c, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Fri May 26 01:10:00 CST 2017, time=2017-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800954, encodeId=27781800954c1, content=<a href='/topic/show?id=3075e3328f7' target=_blank style='color:#2F92EE;'>#研发人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73328, encryptionId=3075e3328f7, topicName=研发人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Jan 24 08:10:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896015, encodeId=35ce18960159a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Sep 01 12:10:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881853, encodeId=38dd18818534a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 08 11:10:00 CST 2017, time=2017-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300000, encodeId=2eda130000035, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Apr 07 05:10:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185348, encodeId=15381853486e, content=反复实践,反复学习,认真推敲,不断提高自己的业务水平。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Wed Apr 05 15:43:36 CST 2017, time=2017-04-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1663472, encodeId=ed1c16634e2b1, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Fri Mar 02 23:10:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844207, encodeId=bc1a184420e8c, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Fri May 26 01:10:00 CST 2017, time=2017-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800954, encodeId=27781800954c1, content=<a href='/topic/show?id=3075e3328f7' target=_blank style='color:#2F92EE;'>#研发人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73328, encryptionId=3075e3328f7, topicName=研发人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Jan 24 08:10:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896015, encodeId=35ce18960159a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Sep 01 12:10:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881853, encodeId=38dd18818534a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 08 11:10:00 CST 2017, time=2017-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300000, encodeId=2eda130000035, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Apr 07 05:10:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185348, encodeId=15381853486e, content=反复实践,反复学习,认真推敲,不断提高自己的业务水平。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Wed Apr 05 15:43:36 CST 2017, time=2017-04-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1663472, encodeId=ed1c16634e2b1, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Fri Mar 02 23:10:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844207, encodeId=bc1a184420e8c, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Fri May 26 01:10:00 CST 2017, time=2017-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800954, encodeId=27781800954c1, content=<a href='/topic/show?id=3075e3328f7' target=_blank style='color:#2F92EE;'>#研发人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73328, encryptionId=3075e3328f7, topicName=研发人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Jan 24 08:10:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896015, encodeId=35ce18960159a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Sep 01 12:10:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881853, encodeId=38dd18818534a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 08 11:10:00 CST 2017, time=2017-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300000, encodeId=2eda130000035, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Apr 07 05:10:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185348, encodeId=15381853486e, content=反复实践,反复学习,认真推敲,不断提高自己的业务水平。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Wed Apr 05 15:43:36 CST 2017, time=2017-04-05, status=1, ipAttribution=)]
    2017-09-01 一闲
  5. [GetPortalCommentsPageByObjectIdResponse(id=1663472, encodeId=ed1c16634e2b1, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Fri Mar 02 23:10:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844207, encodeId=bc1a184420e8c, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Fri May 26 01:10:00 CST 2017, time=2017-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800954, encodeId=27781800954c1, content=<a href='/topic/show?id=3075e3328f7' target=_blank style='color:#2F92EE;'>#研发人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73328, encryptionId=3075e3328f7, topicName=研发人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Jan 24 08:10:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896015, encodeId=35ce18960159a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Sep 01 12:10:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881853, encodeId=38dd18818534a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 08 11:10:00 CST 2017, time=2017-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300000, encodeId=2eda130000035, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Apr 07 05:10:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185348, encodeId=15381853486e, content=反复实践,反复学习,认真推敲,不断提高自己的业务水平。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Wed Apr 05 15:43:36 CST 2017, time=2017-04-05, status=1, ipAttribution=)]
    2017-09-08 liye789132251
  6. [GetPortalCommentsPageByObjectIdResponse(id=1663472, encodeId=ed1c16634e2b1, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Fri Mar 02 23:10:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844207, encodeId=bc1a184420e8c, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Fri May 26 01:10:00 CST 2017, time=2017-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800954, encodeId=27781800954c1, content=<a href='/topic/show?id=3075e3328f7' target=_blank style='color:#2F92EE;'>#研发人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73328, encryptionId=3075e3328f7, topicName=研发人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Jan 24 08:10:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896015, encodeId=35ce18960159a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Sep 01 12:10:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881853, encodeId=38dd18818534a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 08 11:10:00 CST 2017, time=2017-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300000, encodeId=2eda130000035, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Apr 07 05:10:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185348, encodeId=15381853486e, content=反复实践,反复学习,认真推敲,不断提高自己的业务水平。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Wed Apr 05 15:43:36 CST 2017, time=2017-04-05, status=1, ipAttribution=)]
    2017-04-07 lqvr
  7. [GetPortalCommentsPageByObjectIdResponse(id=1663472, encodeId=ed1c16634e2b1, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Fri Mar 02 23:10:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844207, encodeId=bc1a184420e8c, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Fri May 26 01:10:00 CST 2017, time=2017-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800954, encodeId=27781800954c1, content=<a href='/topic/show?id=3075e3328f7' target=_blank style='color:#2F92EE;'>#研发人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73328, encryptionId=3075e3328f7, topicName=研发人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Jan 24 08:10:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896015, encodeId=35ce18960159a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Sep 01 12:10:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881853, encodeId=38dd18818534a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 08 11:10:00 CST 2017, time=2017-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300000, encodeId=2eda130000035, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Apr 07 05:10:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185348, encodeId=15381853486e, content=反复实践,反复学习,认真推敲,不断提高自己的业务水平。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Wed Apr 05 15:43:36 CST 2017, time=2017-04-05, status=1, ipAttribution=)]
    2017-04-05 ylzr123

    反复实践,反复学习,认真推敲,不断提高自己的业务水平。

    0

相关资讯

Nature Genet:吸烟与Y染色体消失,《自然》子刊解密因果效应

吸烟已被认为是导致循环细胞染色体丢失的原因,但之前尚未弄清楚这其中的因果关系。近日,科学家在《Nature Genetics》杂志上揭示了吸烟与Y染色体缺失的因果效应,研究发现Y染色体消失受19个基因区域所调控,他们还强调了Y染色体缺失与癌症易感性之间共享这种遗传结构。

ELIFE:癌症靶向治疗为何“败走麦城”

冷泉港(CSHL)Raffaella Sordella博士课题组验证,某些肿瘤的耐药机制可以形容为“肿瘤的潜伏策略”:肿瘤病灶附近的一小部分细胞能够演变为肿瘤细胞的“卧底”。这些被初次治疗放过了的细胞,随着时间的推移将由一颗种子成长为致命的毒瘤。靶向治疗,是在细胞分子水平上,针对已经明确的致癌位点(该位点可以是肿瘤细胞内部的一个蛋白分子,也可以是一个基因片段),来设计相应的治疗药物,药物进入体内会

Oral Oncol:台湾患者切除颊侧或舌侧鳞状细胞癌的临床愈后比较

尽管患颊侧鳞状细胞癌(SCC)的患者通常会获得较好的愈后,但是其局部防治和存活率通常较舌侧SCC低。这项研究是为了比较罹患两种常见口腔恶心肿瘤的台湾患者的治疗愈后差异。

Nature:两篇论文挑战癌症干细胞概念:癌干细胞与癌症转移有关吗?

科学家们认为干细胞分裂是肿瘤生长所必需的,癌症干细胞能驱动肿瘤生长与转移,由此提出了将去除癌症干细胞作为癌症治疗的靶标之一。然而这在许多类型的癌症中都还没有找到确凿的实验证据。最新一期(3月29日)Nature杂志中,来自日本和美国的科学家通过靶向去除特殊的干细胞群体,发现了这些干细胞在肿瘤发展中的作用,以及对于癌症转移的影响。Lgr5+干细胞小肠上皮细胞层是哺乳动物机体的自我更新支持者,它的

Clin Infect Dis.:哪些类型癌症患者活动性结核进展风险**?

癌症可增加活动性结核进展的风险,但哪些类型癌症的风险最大呢?2017年3月1日发表在《Clin Infect Dis》的一项研究显示,血液学、头颈部和肺癌患者活动性结核进展率比其他癌症患者高9倍。

癌症为何能自愈?肿瘤科医生猜测了这5个原因

癌症自愈虽然是小概率事件,但是却千真万确地出现过。来源丨宋芳华作者丨医学界肿瘤频道2016 年 6 月 17 日,由英国巴斯大学的 Momna Hejmadi 在《谈话》杂志上发表了一篇题为“为什么某些癌症突然会不治自愈”的文章,再次引起我们的思索,那些自愈的癌症是如何产生的?目前,癌症自愈的原因尚未明确,但是癌症是复杂的,癌症自愈的原因也不可能只有一个。1. 免疫系统由于某种原因产生了针对肿瘤细